ALLR
Allarity Therapeutics, Inc.
$1.61
+1.90%
$24.4M
No data for this timeframe.
Vol
Market Cap$24.4M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders4 funds
Inst. Value$563.7K
Inst. Activity2 buys / 0 sells
SEC Reports6
Press Releases4
Recent Activity
May 15, 2026
announcement
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
<p align="center"><i>- Stenoparib clinical development continues in relapsed small cell lung cancer
May 11, 2026
SEC
Jesper Hoeiland filed a Form 3 initial statement of beneficial ownership with Allarity Therapeutics, disclosing zero sha
3 — Impact 1/10
May 6, 2026
SEC
Allarity Therapeutics announced that its Phase 3 API manufacturing campaign for stenoparib is on track for completion by
8-K — Impact 3/10
Apr 27, 2026
SEC
Allarity Therapeutics' S-3 shelf registration has become effective, allowing the company to issue up to $75 million in s
EFFECT — Impact 3/10
Jan 28, 2026
Insider
Jensen Thomas sold 200,000 shares
CEO @ $0.00 ($0.00)
Jan 28, 2026
Insider
McLaughlin Gerald W. sold 45,000 shares
Director @ $0.00 ($0.00)
Jan 28, 2026
Insider
Graff Jeremy R. sold 133,333 shares
See Remarks @ $0.00 ($0.00)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
247,612 shares ($267.4K)
Price Targets
$10.25
+536.6% upside
Strong Buy
Current $1.61
Low $10.25
Median $10.25
High $10.25
1 analysts
$10.25
$10.25
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Apr 10, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.25 | $-0.25 — $-0.25 | -67% YoY | 1 |
| Next Q | $-0.25 | $-0.25 — $-0.25 | -32% YoY | 1 |
| Current FY | $-0.92 ▲ +4.2% | $-0.92 — $-0.92 | -18% YoY | 1 |
| Next FY | $-0.97 | $-0.97 — $-0.97 | -5% YoY | 1 |
Latest Reports
NEUTRAL
3
1/10
Jesper Hoeiland filed a Form 3 initial statement of beneficial ownership with Allarity Therapeutics, disclosing zero sha
May 11, 2026
NEUTRAL
Press
2/10
Allarity Therapeutics CEO Thomas Jensen will present at Precision Medicine Forum Europe 2026 on May 11, discussing steno
May 8, 2026
NEUTRAL
8-K
3/10
Allarity Therapeutics announced that its Phase 3 API manufacturing campaign for stenoparib is on track for completion by
May 6, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $267.4K | DOUBLED |
| VANGUARD GROUP INC | $266.4K | NEW |
| TWO SIGMA INVESTMENTS, LP | $29.7K | ADD |
| BANK OF AMERICA CORP | $151.00 | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jan 28, 2026 | Jensen Thomas | A | $0.00 |
| Jan 28, 2026 | McLaughlin Gerald | A | $0.00 |
| Jan 28, 2026 | Graff Jeremy | A | $0.00 |
| Jan 28, 2026 | Ervin Jeffrey | A | $0.00 |
| Jan 7, 2026 | Hoeiland Jesper | A | $0.00 |
4 institutional holders with $563.7K total value (521,952 shares) as of 2025-Q4. Top holders: RENAISSANCE, VANGUARD, TWO. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 247,612 | $267.4K | 47.4% | DOUBLED +274.1% |
| 2 | VANGUARD GROUP INC | 246,708 | $266.4K | 47.3% | NEW |
| 3 | TWO SIGMA INVESTMENTS, LP | 27,492 | $29.7K | 5.3% | ADD +97.6% |
| 4 | BANK OF AMERICA CORP /DE/ | 140 | $151.00 | 0.0% | DOUBLED +263.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 66,186 | 247,612 | +274.1% | $267.4K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 13,910 | 27,492 | +97.6% | $29.7K | 2025-Q4 |
| VANGUARD GROUP INC | NEW | — | 246,708 | — | $389.8K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 66,186 | — | $104.6K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 13,910 | — | $22.0K | 2025-Q3 |
| UBS Group AG | EXIT | 47,984 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 300 | 47,984 | +15894.7% | $48.5K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 38 | 138 | +263.2% | $139.00 | 2025-Q2 |
| MORGAN STANLEY | EXIT | 23,311 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MORGAN STANLEY | NEW | — | 23,311 | — | $21.8K | 2025-Q1 |
| UBS Group AG | EXIT | 18,452 | 0 | -100.0% | $0.00 | 2024-Q4 |
5 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 28, 2026 | Jensen Thomas | CEO | A | 200,000 | $0.00 | $0.00 |
| Jan 28, 2026 | McLaughlin Gerald W. | Director | A | 45,000 | $0.00 | $0.00 |
| Jan 28, 2026 | Graff Jeremy R. | See Remarks | A | 133,333 | $0.00 | $0.00 |
| Jan 28, 2026 | Ervin Jeffrey S | CFO | A | 150,000 | $0.00 | $0.00 |
| Jan 7, 2026 | Hoeiland Jesper | Director | A | 25,000 | $0.00 | $0.00 |
6 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.8/10.
NEUTRAL
3
1/10
Jesper Hoeiland filed a Form 3 initial statement of beneficial ownership with Allarity Therapeutics,
May 11, 2026
NEUTRAL
8-K
3/10
Allarity Therapeutics announced that its Phase 3 API manufacturing campaign for stenoparib is on tra
May 6, 2026
NEUTRAL
EFFECT
3/10
Allarity Therapeutics' S-3 shelf registration has become effective, allowing the company to issue up
Apr 27, 2026
NEUTRAL
S-3/A
2/10
Allarity Therapeutics filed an amendment to its S-3 shelf registration to update the auditor consent
Apr 24, 2026
BULLISH
8-K
6/10
Allarity Therapeutics presented two posters at the AACR 2026 Annual Meeting highlighting new data on
Apr 22, 2026
BULLISH
8-K
8/10
Allarity Therapeutics reported full-year 2025 financial results, showing improved net loss of $11.2
Apr 21, 2026
NEUTRAL
2/10
Allarity Therapeutics CEO Thomas Jensen will present at Precision Medicine Forum Europe 2026 on May
May 8, 2026
BULLISH
7/10
Allarity Therapeutics announced a Notice of Allowance from the USPTO for a patent covering its DRP®
Apr 27, 2026
BULLISH
7/10
Allarity Therapeutics reported its 2025 financial results, highlighting a $14.7 million cash positio
Mar 31, 2026
BULLISH
7/10
Allarity Therapeutics has closed a $20 million non-convertible debt financing with Streeterville Cap
Mar 6, 2026
Current analyst consensus: Strong Buy (86% buy). Based on 7 analysts: 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$10.25 mean target
+536.6% upside
Strong Buy (1.00)
$10.25 Low
$10.25 High
| Metric | Value |
|---|---|
| Current Price | $1.61 |
| Target Low | $10.25 |
| Target Mean | $10.25 |
| Target Median | $10.25 |
| Target High | $10.25 |
| # Analysts | 1 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.25 | $-0.25 | $-0.25 | -66.7% | +0.0% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.25 | $-0.25 | $-0.25 | -31.6% | +0.0% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.92 | $-0.92 | $-0.92 | -18.0% | +4.2% | 1↑ 0↓ | $0.0B | -92.2% | 1 |
| Next FY 2027-12-31 |
$-0.97 | $-0.97 | $-0.97 | -5.4% | +0.0% | 0↑ 1↓ | $0.0B | -100.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.250 | |
| 7d ago | $-0.250 | |
| 30d ago | $-0.250 | |
| 60d ago | $-0.240 | -0.010 |
| 90d ago | $-0.240 | -0.010 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Apr 10, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 15, 2026
announcement
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
<p align="center"><i>- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced
May 13, 2026
earnings_calendar
ALLR Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
ALLR Q1 2026 Earnings Scheduled — 2026-05-11
May 9, 2026
earnings_calendar
ALLR Q1 2026 Earnings Scheduled — 2026-05-09
May 8, 2026
announcement
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
<p align="center"> <br></p>
Apr 27, 2026
announcement
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
<p><b>TARPON SPRINGS, Fla., </b>April 27, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage ph
Apr 1, 2026
Clinical Trial
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Phase Phase 2 — TERMINATED
Mar 31, 2026
earnings
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
<p align="center"> <br></p>
Mar 31, 2026
earnings_calendar
ALLR Q4 2025 Earnings After Market Close — 2026-03-31
Mar 6, 2026
announcement
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
<p align="center"> <br></p>